<DOC>
	<DOCNO>NCT02446366</DOCNO>
	<brief_summary>This phase I trial study side effect best dose hypofractionated stereotactic body radiation therapy ( SBRT ) treat patient prostate cancer remove surgery . Hypofractionated SBRT delivers higher dos radiation therapy short period time may kill tumor cell may fewer side effect standard radiation therapy .</brief_summary>
	<brief_title>Hypofractionated Stereotactic Body Radiation Therapy Treating Patients With Prostate Cancer That Was Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerated dose-per-fraction SBRT prostate fossa follow prostatectomy base acute toxicity ( &lt; 90 day ) . SECONDARY OBJECTIVES : I . To describe acute ( &lt; 90 day ) toxicity adverse event associate hypofractionated SBRT administer prostate bed post-prostatectomy setting . II . To describe late ( &gt; 90 day treatment ) toxicities adverse event associate hypofractionated SBRT administer prostate bed post-prostatectomy setting . TERTIARY OBJECTIVES : I . To describe patient-reported toxicity/quality life ( QOL ) follow hypofractionated SBRT treatment . OUTLINE : This dose-escalation study . Patients undergo 5 , 10 , 15 fraction hypofractionated SBRT daily 1-3 week . After completion study treatment , patient follow 2 , 6 , 13 week 6 , 9 , 12 , 18 , 24 , 30 36 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Adenocarcinoma prostate treat primarily radical prostatectomy Any type radical prostatectomy permit include retropubic , perineal , laparoscopic robotically assist ; time limit date radical prostatectomy One follow pathologic classification T3N0 disease without positive surgical margin T2N0 disease without positive surgical margin Those T2N0 disease negative margin must detectable prostatespecific antigen ( PSA ) follow radical prostatectomy Must undetectable PSA prostatectomy since rise postoperative PSA 0.2 ng/mL great Zubrod performance status 0 1 No distant metastasis , base follow workup within 60 day prior registration Magnetic resonance imaging ( MRI ) pelvis Bone scan sodium fluoride positron emission tomography ( PET ) , suspicious MRI plain Xrays rule bone metastasis Patients androgen deprivation therapy Ability understand willingness sign studyspecific inform consent prior study entry N1 patient ineligible , lymph node ( LN ) enlargement &gt; 1.5 cm compute tomography ( CT ) MRI pelvis , unless LN biopsy proven negative Gross residual disease prostate fossa appreciate wither digital rectal examination ( DRE ) imaging , unless biopsy proven contain cancer Patients expose neoadjuvant chemotherapy chemotherapy prostatectomy Prior radiation kind prostate gland pelvis Prior brachytherapy allow History inflammatory colitis active severe comorbidities Patients immunosuppressant medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>